Osteopore

Osteopore FCF per Share

The Free Cash Flow per Share of Osteopore (OSX.AX) as of Oct 28, 2026 is -0.01 AUD. In the previous year, Free Cash Flow per Share was -0.03 AUD — a change of -55.37% (higher).

FCF per Share

-0.01AUD

YoY

-55.37%

Last updated:

Free Cash Flow per Share of Osteopore is 2025 -0.01 AUD. Free Cash Flow per Share of Osteopore was 2024 -0.03 AUD. It decreases by -55.37% higher compared to the previous year.

The Osteopore FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.01 AUD
Jan 1, 2019
-0.06 AUD
Jan 1, 2020
-0.05 AUD
Jan 1, 2021
-0.03 AUD
Jan 1, 2022
-0.05 AUD
Jan 1, 2023
-0.36 AUD
Jan 1, 2024
-0.03 AUD
Jan 1, 2025
-0.01 AUD
The Osteopore FCF per Share history
YEARFCF per ShareYoY
-0.01AUD-55.37%
-0.03AUD-91.56%
-0.36AUD+641.37%
-0.05AUD+42.92%
-0.03AUD-33.94%
-0.05AUD-17.00%
-0.06AUD+492.78%
-0.01AUD+953.47%
-0.00AUD-85.25%
-0.01AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Osteopore Stock analysis

What does Osteopore do? Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgeries. The company commercializes bespoke products engineered to facilitate bone healing, utilizing patented technology that fabricates micro-structured scaffolds through 3D printing and bioresorbable materials. Key products include Osteoplug in plug and strip configurations for craniotomy gap filling, Osteomesh, and Osteoplug-C for craniofacial applications. These solutions support bone tissue integration from the skull to the bone flap, targeting procedures such as cranioplasty, craniosynostosis, and guided bone regeneration. The company serves medical professionals and healthcare facilities requiring advanced bone regeneration solutions. Its products are designed for specific surgical applications including craniotomy, orbital floor reconstruction, socket preservation, and minimally invasive skull base surgery. Osteopore Ltd. focuses on delivering patient-specific implants (PSI) for cranial and mandibular procedures, alongside solutions for burr hole restoration with shunt drainage systems. These offerings cater to specialized surgical segments demanding precision and biocompatibility. Osteopore Ltd.'s revenue streams derive from the sale of its proprietary implant systems to hospitals and surgical centers. The company’s technology enables the production of custom implants that address complex bone healing needs, particularly in neurosurgery, orthopaedics, and maxillofacial procedures. By providing tailored solutions for cranioplasty, craniosynostosis, and guided bone regeneration, the company meets the demands of healthcare providers seeking effective bone regeneration technologies. Osteopore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Osteopore stock

Free Cash Flow per Share of Osteopore is -0.01 AUD in 2025.

Free Cash Flow per Share of Osteopore changed from -0.03 AUD to -0.01 AUD, representing a -55.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Osteopore since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Osteopore

All Key Metrics — Osteopore